U.S. FDA Approves Mylan and Biocon’s Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers

December 1, 2017

Responsive image

HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Dec. 1, 2017 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan’s Ogivri™ (trastuzumab-dkst), a…

Category: Precious Metals